Literature DB >> 4037794

Modulation of platelet-activating factor (PAF) synthesis and release from human polymorphonuclear leukocytes (PMN): role of extracellular albumin.

J C Ludwig, C L Hoppens, L M McManus, G E Mott, R N Pinckard.   

Abstract

Human neutrophilic polymorphonuclear leukocytes (PMN) stimulated with N'-formyl-methionyl-leucyl-phenylalanine (FMLP) in the presence of cytochalasin B but in the absence of human serum albumin (HSA) synthesized only small amounts of platelet-activating factor (PAF) that attained maximum levels within 60-120 s after stimulation; in addition, no release of PAF occurred. However, in the presence of 2.5 mg HSA/ml, there was a threefold increase in PAF synthesis, 30-40% of which was released within 5 min after FMLP stimulation. In the presence of 50 mg HSA/ml there was at least a fourfold increase in PAF synthesis and release, with maximal synthesis occurring 10-20 min after stimulation. Thus, the presence of HSA during PMN stimulation not only induced an albumin dose-dependent increase in PAF release but significantly augmented the synthesis of PAF. In contrast to PAF synthesis and release, the presence or absence of HSA had no effect upon lysosomal enzyme secretion from FMLP-stimulated PMN, which was maximal within 30-60s after stimulation. These results demonstrate that HSA plays an essential role in vitro in the synthesis and release of PAF from human PMN, and support the hypothesis that there is a cyclic PAF synthesis-release coupling mechanism in the stimulated human PMN.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4037794     DOI: 10.1016/0003-9861(85)90555-7

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

1.  Determination of platelet-activating factor by a chemiluminescence method and its application to stimulated guinea pig neutrophils.

Authors:  Y Hasegawa; E Kunow; J Shindou; H Yuki
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

Review 2.  Platelet-activating factor: receptors and signal transduction.

Authors:  W Chao; M S Olson
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

3.  1-Acyl-2-acetyl-sn-glycero-3-phosphocholine from stimulated human polymorphonuclear leukocytes.

Authors:  K Satouchi; M Oda; K Saito
Journal:  Lipids       Date:  1987-04       Impact factor: 1.880

4.  Platelet-leukocyte interaction: activation of rabbit platelets by FMLP-stimulated neutrophils.

Authors:  E Coëffier; D Joseph; M C Prévost; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

5.  Platelet-activating factor regulates phospholipid metabolism in human neutrophils.

Authors:  J S Tou
Journal:  Lipids       Date:  1989-09       Impact factor: 1.880

6.  Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macrophages: implications for the biologically active form of PAF.

Authors:  G Grigoriadis; A G Stewart
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

7.  Autoradiographic localization of platelet-activating factor (PAF) binding sites in the rabbit endometrium during the peri-implantation period.

Authors:  G B Kudolo; M Kasamo; M J Harper
Journal:  Cell Tissue Res       Date:  1991-08       Impact factor: 5.249

8.  Transient activation of 1-O-alkyl-sn-glycero-3-phosphocholine: acetyl-CoA acetyltransferase during the incubation of macrophages.

Authors:  T Sugiura; T Fukuda; N N Cheng; K Waku
Journal:  Lipids       Date:  1991-11       Impact factor: 1.880

9.  Biosynthesis of platelet-activating factor by cultured rat Kupffer cells stimulated with calcium ionophore A23187.

Authors:  W Chao; A Siafaka-Kapadai; M S Olson; D J Hanahan
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

10.  Specific binding of antibodies to platelet-activating factor (PAF) as demonstrated by thin-layer chromatography/immunostaining.

Authors:  K Karasawa; N Satoh; T Hongo; Y Nakagawa; M Setaka; S Nojima
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.